Floatz logo

IBUPROFEN

Ulcer

AmgenSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Ulcer cohort.

Asset / SponsorPhaseRating
Famotidine
Amgen
Phase 3BB
Auto-Cd34+ Cells
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 1/2CCC
NEPENTHE
Soroka University Medical Center
N/AD

Same molecule, other indications

IBUPROFEN is also rated in:

chronic pain syndromeDormant
BBB
Indicative ·
72 / 100
View asset →
migraine disorderDormant
BBB
Indicative ·
72 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →